Sir,
145mg/m 2 and cyclophosphamide 720 mg/m 2 administered as a infusion on day one, repeated every three weeks. Treatment given on day 1 was preceded by dexametasone 4 mg i.v. and granisetron 3 mg i.v. for the prophylaxis of nausea and vomiting. The same anti-emetic treatment was repeated i.v.on day 2 and orally on days 3 and 4. The first treatment cycle was uneventful. Four days after administration of the second cycle the patient was admitted to our clinic with hand-foot syndrome(HFS), associated with nail changes on hand (hyperpigmentation) and maculopapuler eruptions on the trunk (Figure 1 ,2,3,4 and 5). In our case, HFS was associated cutaneous reactions which progress to the body of the patient. After the first episode of HFS, interruption of therapy was necessary.The patient was used pyridoxine with dose of 100mg /d.and local thearpy with cooling hand and foot baths. Chemotherapy was restarted according to the original scheme after 2 weeks. Exposure of the hands and feet to heat or friction increases the drug leakage from the capillaries. This leakage of drug results in redness, tenderness, peeling and numbness. HFS occurs most frequently in therapy with 5-Fluoruracil (5-FU), capecitabine ,vinorelbin, continuous-infusion doxorubicin, docetaxel and high-dose Interleukin-2. There is no evidence in the literature that HFS prefers a race or population group. Palmoplantar erythemas of other origins are common and differantial diagnosis must be done from that they not become worse with chemotherapy and they exist prior the chemotherapy. Contact eczema, allergic cantact and druginduced eczamas, Hand-Foot-Mouth disease, sickle-cell anemia,eritema multiforme must be added to the differential diagnostic considerations.The approaches to managing handfoot syndrome is include pyridoxine(vitamin B6), corticosteroids and dimethyl-sulfoxide (DMSO),avoid exercise, manuel labor,and to contact with the hot water.
